Soujanya Ravi, Author at PharmaDeviceNews

Can PharmAla’s three year stability program de risk MDMA distribution challenges?

PharmAla will generate three year stability data for LaNeo MDMA. Discover how this could shape packaging, regulation, and commercialization.

Recursion Pharmaceuticals spotlights its self-driving lab model at NVIDIA GTC 2026. Explore what this means for AI drug discovery and regulation.

GE HealthCare secures FDA clearance for next-generation SIGNA MRI. Explore clinical impact, workflow gains, and market implications.

Dror Ortho-Design secures FDA clearance for ZSmile. Explore what pneumatic aligners mean for orthodontic innovation and adoption.

Profusa secures Lumee Oxygen orders ahead of EU MDR clearance. Discover what this means for CLTI monitoring and 2026 commercialization.

Starton Therapeutics advances STAR-LLD in Phase 2a. Explore how continuous lenalidomide delivery could reshape multiple myeloma care.

Moleculin secures Japanese patent for Annamycin reconstitution. Discover what this means for AML development and global market strategy.

ViroMissile expands its IDOV-Immune Phase I trial to U.S. sites after FDA IND clearance. Discover what this means for systemic oncolytic therapy.

EU approves 7.2 mg Wegovy for obesity. Explore what this means for efficacy, competition and reimbursement across Europe.

Phase 1 PK data bring Ameluz closer to broader FDA review. Explore the regulatory stakes and market impact in actinic keratosis.